LivingGLP1
Study S000291

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT05478707
Acronym
MCD-1
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
TRIPLE
Status
RECRUITING
Enrollment
47
Start
2023-10-05
Primary completion
2028-06-30
Lead sponsor
AdventHealth Translational Research Institute
Conditions
Diabetes Mellitus, Type 1; Endothelial Dysfunction
Interventions
DRUG:Dulaglutide; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Microvascular blood volume (MBV) [At baseline and after 14 weeks of treatment.]

Linked records (15)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0018537Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Lancet (London, England)
2019Randomized trialPMID 31189511DOIregistry reference BACKGROUND:31189511
R0012223Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF, Lancet (London, England)
2018Randomized trialPMID 30291013DOIregistry reference BACKGROUND:30291013
R0014882Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B, Diabetes, obesity & metabolism
2018Other trialPMID 28817231DOIregistry reference BACKGROUND:28817231
R0016601Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V, Cardiovascular diabetology
2018Randomized trialPMID 29310645DOIregistry reference BACKGROUND:29310645
R0021191Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Lepore JJ, JACC. Heart failure
2016Randomized trialPMID 27039125DOIregistry reference BACKGROUND:27039125
R0021667Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats.
Chai W, American journal of physiology. Endocrinology and metabolism
2016PreclinicalPMID 27436611DOIregistry reference BACKGROUND:27436611
R0022060Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27295427DOIregistry reference BACKGROUND:27295427
R0022278Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, The New England journal of medicine
2016Randomized trialPMID 27633186DOIregistry reference BACKGROUND:27633186
R0025363Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Mathieu C, Diabetes care
2016Randomized trialPMID 27506222DOIregistry reference BACKGROUND:27506222
R0025614Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Ahrén B, Diabetes care
2016Randomized trialPMID 27493132DOIregistry reference BACKGROUND:27493132
R0020195GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
Crisci I, Acta diabetologica
2015OtherPMID 26293127DOIregistry reference BACKGROUND:26293127
R0016652Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Nauck M, Diabetes care
2014Randomized trialPMID 24742660DOIregistry reference BACKGROUND:24742660
R0024447Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells.
Batchuluun B, Atherosclerosis
2014OtherPMID 24401231DOIregistry reference BACKGROUND:24401231
R0023273Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
Irace C, Diabetes & vascular disease research
2013Other trialPMID 22732108DOIregistry reference BACKGROUND:22732108
R0030559Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.
Basu A, American journal of physiology. Endocrinology and metabolism
2007Randomized trialPMID 17711996DOIregistry reference BACKGROUND:17711996